Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.64)
# 718
Out of 5,182 analysts
124
Total ratings
54.62%
Success rate
23.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.15 | +180.78% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $7.99 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $37.80 | +32.28% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $14.50 | -13.79% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $81.86 | +14.83% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $11.13 | +79.69% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $225.79 | -3.89% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $6.53 | +22.51% | 11 | Mar 7, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $61.21 | +19.26% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $2.34 | +412.82% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $3.52 | +113.07% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.92 | +773.65% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $2.37 | +2,410.55% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.66 | +29,872.75% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.15
Upside: +180.78%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $7.99
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $37.80
Upside: +32.28%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $14.50
Upside: -13.79%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $81.86
Upside: +14.83%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $11.13
Upside: +79.69%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $225.79
Upside: -3.89%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $6.53
Upside: +22.51%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $61.21
Upside: +19.26%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $2.34
Upside: +412.82%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $3.52
Upside: +113.07%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.92
Upside: +773.65%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $2.37
Upside: +2,410.55%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.66
Upside: +29,872.75%